ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0419

No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors

Romy Hansildaar1, Reinder Raadsen1, Maaike Heslinga2 and Michael Nurmohamed2, 1Reade, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, rheumatoid arthritis, TNF-blocking Antibody

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-fold higher risk of venous thromboembolism (VTE) compared with the general population. The immune system and hemostatic system are closely linked by a shared origin. Inflammation affects thrombotic responses by upregulating procoagulants and downregulating anticoagulants and fibrinolysis. Tumor necrosis factor (TNF), an important mediator in the inflammatory pathway, induces a disbalance between the coagulation system and fibrinolytic system, resulting in a hypercoagulable state. In addition, several studies have suggested that some Janus kinase-inhibitors (JAKi) might be associated with an increased risk for VTE. However, the underlying pathogenic mechanisms have yet to be elucidated. Our objective was to compare changes in hemostatic parameters during treatment with TNF-blockers and JAKi in RA.

Methods: Biomarkers for the coagulation system, including D-dimer, fibrinogen, PT, aPTT, F1+2, TAT, F IX and vWF, were prospectively measured in 121 consecutive RA patients: 83 patients treated with aTNF and 38 patients with JAKi. Data were collected at baseline, after 1, 3, and 6 months.

Results: Mean age for all patients was 57 (±14) years, 76% were female. Mean DAS28-CRP at baseline for TNF-inhibitor group was 3.6 (±1.3) and 4.1 (±1.4) for JAKi group, steadily declining in aTNF users, while decreasing in JAKi users with an intermittent peak at 3 months. Baseline coagulation markers levels were comparable between the groups. D-dimer and vWF levels were slightly higher in the JAKi group (p = 0.30 and p = 0.08, respectively), while F IXa levels were lower (p = 0.17). D-dimer and fibrinogen levels steadily declined in the aTNF group, while fluctuating in the JAKi group, with a peak at 3 months with a subsequent decline thereafter (Figure 1). In aTNF users, TAT increased slightly during follow-up. VWF, PT and aPTT remained relatively stable, while F IXa and F 1+2 showed an increase after 3 months of follow-up, after which they returned to baseline. In JAKi users, D-dimer, fibrinogen, VWF and F 1+2 fluctuated, with a peak after 3 months and then a subsequent decline. F IX and PT initially decreased slightly but increased steadily after 6 months, while TAT and aPTT remained stable during follow-up.

Conclusion: The pro-thrombotic tendency in active RA declined during effective treatment with both aTNF as well as JAKi. A gradually decrease in D-dimer and fibrinogen was seen after 6 months of treatment. The transient increase of coagulation activation in JAKi users at three months coincided with increased disease activity. Altogether, our data suggests that an increased VTE risk in the first six months due to wither treatment aTNF or JAKi seems unlikely. Whether or not the risk increases beyond this time period remains to be investigated.

Supporting image 1

Table 1: Progression of mean coagulation markers. * Significantly different from baseline, p < 0,05. TNF = tumor necrosis factor, JAK = Janus kinase, F1+2= prothrombin fragment 1+2, VWF= von Willebrand factor, TAT= thrombin-antithrombin complex, FIX= Factor 9, PT = prothrombin time, aPTT = activated partial thromboplastin time.

Supporting image 2

Figure 1: Progression of coagulation markers. F1+2= prothrombin fragment 1+2, VWF= von Willebrand factor, TAT= thrombin-antithrombin complex, FIX= Factor 9, PT = prothrombin time, aPTT = activated partial thromboplastin time.


Disclosures: R. Hansildaar: None; R. Raadsen: None; M. Heslinga: None; M. Nurmohamed: None.

To cite this abstract in AMA style:

Hansildaar R, Raadsen R, Heslinga M, Nurmohamed M. No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/no-clinically-relevant-changes-in-coagulation-activation-between-patients-initiating-tnf-blockers-versus-jak-inhibitors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/no-clinically-relevant-changes-in-coagulation-activation-between-patients-initiating-tnf-blockers-versus-jak-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology